DNTH: Rega marang dodolan Dianthus Therapeutics Inc
The lack of operating cash flow and a strategic reliance on R&D investments create a certain developmental inertia for Dianthus Therapeutics (DNTH). The price-to-sales ratio visualizes these consolidation phases, with the current metric standing at 1898.80. The business foundation is based on robotic antibody screening and strict logistical control during the transportation of reagents for clinical trials.
Rincian metrik lan analitis perusahaan Dianthus Pharma (DNTH)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Dianthus Therapeutics|DNTH - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Dianthus Corp|DNTH - Gunggung utang perusahaan|Utang marang modal buku Dianthus Pharma|DNTH - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Dianthus Therapeutics|Rasio cepet dianthustx.com
- indikator pendapatan resik lan kelipatan nilai:
DNTH - Bathi resik perusahaan|Prakiraan bathi perusahaan Dianthus Therapeutics|DNTH - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Dianthus Therapeutics Inc|DNTH - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Dianthus Pharma|DNTH - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Dianthus Therapeutics|DNTH - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan dianthustx.com|DNTH - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Dianthus Therapeutics
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:dianthustx.com
The P/S ratio compares the market value of a business to its generated sales, allowing for the determination of the premium paid per unit of revenue in a fundamental valuation. By analyzing the P/S chart, an investor can diagnose the capitalization stability of Dianthus Therapeutics (DNTH), where the diversification of protein synthesis contracts minimizes raw material risks and ensures stable margins during the development of antibodies for treating rare pathologies.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX (Protagonist Corp) - Rasio kapitalisasi marang pendapatan|IMVT: Multiplikator P/S|KNSA - Koefisien rega marang pendapatan|GRFS (Grifols) - Multiplikator P/S|Multiplikator P/S Adaptive Biotech|Rasio rega marang pendapatan Celldex (CLDX)|Aurinia Corp - Rasio kapitalisasi marang pendapatan|BioCryst - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan VERA (veratx.com)|Pharvaris - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ABCL (AbCellera Biologics Inc.)|TRML (Tourmaline Corp) - Kapitalisasi marang pendapatan|Precigen Corp (PGEN) - Multiplikator P/S|Rasio rega marang pendapatan Pharming Group N.V.|nektar.com (NKTR) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan UPB (Upstream Bio)|ZBIO (Zenas Bio) - Rasio kapitalisasi pasar marang pendapatan|Immunome Corp - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan GOSS (Gossamer Bio Corp.)|KalVista Pharmaceuticals - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan SEPN (septerna.com)|PVLA: Multiplikator P/S|Rega marang dodolan Savara Inc (SVRA)|Rasio rega marang pendapatan Rigel Pharmaceuticals Inc|ANAB: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ATXS|Multiplikator P/S engene.com (ENGN)|Rasio rega marang pendapatan RAPT Therapeutics RAPT|JBIO (Aerovate Therapeutics, Inc.) - Rasio rega marang dodolan|Aclaris - Multiplikator P/S|Rega marang dodolan Kyverna Therapeutics, Inc|TLSA (Tiziana Life Sciences) - Kapitalisasi marang pendapatan|cabalettabio.com (CABA) - Multiplikator P/S|Kapitalisasi marang pendapatan VTYX|THTX (Theratechnologies, Inc.) - Kapitalisasi marang volume dodolan|Multiplikator P/S AVTX|Koefisien rega marang pendapatan Eledon Pharmaceuticals, Inc|Multiplikator P/S AGEN (Agenus)|CLYM - Kapitalisasi marang pendapatan|ZURA - Rasio rega marang pendapatan|Koefisien rega marang pendapatan aTyr Pharma Inc ATYR|ADAG: Multiplikator P/S|Rasio kapitalisasi marang pendapatan IMA|Rasio rega marang pendapatan Shattuck Labs Inc|Rasio kapitalisasi marang pendapatan EQ (Equillium Bio)|Kapitalisasi marang pendapatan CNTB (Connect Biopharma)|Kapitalisasi marang volume dodolan IMUX|Multiplikator P/S ATRA (Atara Bio)|Rasio kapitalisasi pasar marang pendapatan IFRX|XFOR - Rasio rega marang pendapatan|Rasio rega marang dodolan ACET|CELU: Multiplikator P/S|INmune Bio Inc - Rasio kapitalisasi pasar marang pendapatan|BRNS (Barinthus Bio) - Multiplikator P/S|Multiplikator P/S Kezar Life Sciences Inc|Rasio rega marang pendapatan SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Enlivex Therapeutics Ltd. ENLV|QTTB - Kapitalisasi marang pendapatan|GeoVax Labs Inc - Multiplikator P/S|EDSA - Multiplikator P/S|IBIO (iBio, Inc.) - Kapitalisasi marang pendapatan|Carisma Therapeutics Inc. - Rasio kapitalisasi pasar marang pendapatan|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|Bolt Bio (BOLT) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|Kapitalisasi marang pendapatan aptevotherapeutics.com APVO|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX - Kapitalisasi marang pendapatan|GRI: Kapitalisasi marang pendapatan|XRTX - Multiplikator P/S|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan REVB|INDP (Indaptus Therapeutics) - Multiplikator P/S|Rega marang dodolan scinai.com SCNI|Multiplikator P/S CALI|affimed.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ALLK (Allakos)|Koefisien rega marang pendapatan HOOKIPA Pharma, Inc. (HOOK)|IGM Bio - Multiplikator P/S|ITOS - Multiplikator P/S|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan TCBP|Kapitalisasi marang pendapatan THRD
